The fusion of artificial intelligence (AI), quantum computing, and biosciences is catapulting the global healthcare sector into a transformative era, with AI-driven biotech investments projected to exceed $1.7 trillion by the end of 2025. This seismic shift was the focal point at GITEX GLOBAL 2025, the world’s premier tech and AI extravaganza, held from October 13-17 at the Dubai World Trade Centre (DWTC). The 45th edition drew a record 6,800 exhibitors, 2,000 startups, and delegates from 180 countries, spotlighting digital health and biotech as the week’s most electrifying themes—from genome editing and neurotech to quantum-accelerated drug discovery.
What once demanded years of laborious research can now be simulated, modeled, and validated in days, thanks to intelligent computing breakthroughs. With pharmaceutical R&D costs averaging $2.23 billion per asset, these innovations promise to slash timelines from decades to months, addressing the 88% clinical trial failure rate in the U.S. and unlocking treatments for underserved conditions. GITEX GLOBAL emerged as the ultimate arena where visionaries redefined the „science of life,“ blending cutting-edge tech with real-world wellness.
AI’s Ascendancy: Rewriting Genes and Minds
On the main stage, Mammoth Biosciences‘ CEO and Co-Founder Trevor Martin ignited discussions with „rewriting the code of life,“ showcasing AI-enhanced CRISPR for rapid gene-editing therapies. „We have programs across liver, muscle, and brain tissues, actively curing genetic diseases by altering DNA,“ Martin revealed. Starting with rare disorders, Mammoth’s ultracompact CRISPR systems—proven in non-human primate studies for efficient muscle editing via single AAV delivery—could save millions of lives. Their NanoCas nuclease, presented at ASGCT 2025, overcomes delivery hurdles for in vivo editing, positioning Mammoth as a leader in curative therapies.
Neurotech stole the spotlight with Paradromics‘ CEO Matt Angle unveiling the Connexus Brain-Computer Interface (BCI). Following the world’s first successful human implant in June 2025—recording neural activity in under 20 minutes—Paradromics is gearing up for a late-2025 clinical trial to enable speech for those with motor impairments. By decoding motor cortex signals into instant speech via high-data-rate AI, the device restores connection, with trials assessing long-term safety and quality-of-life impacts. Principal investigators Dr. David Brandman and Dr. Daniel Rubin will lead this pivotal study, building on sheep trials that demonstrated class-leading data longevity.
In „Genomics Beyond Humans: Unlocking Evolution’s Drug Library,“ Fauna Bio’s CEO Ashley Zehnder highlighted mammal genomes as an untapped reservoir for therapies. Drawing from species like the spiny mouse—which regenerates spinal cord, brain, and kidney tissues—Fauna’s AI-driven analysis uncovers adaptive mechanisms for human medicine, barely scratching the surface of global biodiversity’s potential.
Quantum Leaps in Drug Discovery
SandboxAQ’s CEO Jack Hidary introduced Large Quantitative Models (LQMs)—trained on numbers, equations, molecules, and atoms—to revolutionize R&D. These quantum algorithms enable virtual simulators that test particles millions of times faster, compressing timelines dramatically. In October 2025, SandboxAQ partnered with Bahrain’s Mumtalakat sovereign fund to deploy physics- and biology-trained models, targeting $1 billion in biotech assets and accelerating discoveries in structure-based drug design. Their AQ FEP method, blending AI and quantum principles on classical hardware, has drawn collaborations with AstraZeneca and Sanofi, promising to lower costs and risks in precision immunotherapy. A $95 million funding round in July 2025 bolsters this push, emphasizing quantitative AI for physical systems like cybersecurity and quantum simulation.
Liquid AI’s CEO Ramin Hasani debuted liquid neural networks—bio-inspired by microscopic worms—for real-time adaptation, mimicking living intelligence to enhance predictive diagnostics and personalized care.
Systemic Overhaul: From Sick Care to Health Intelligence
The session „The $10 Trillion Transition: From Sick Care to Health Intelligence“ featured M42 Group CEO Dimitris Moulavasilis and Cleveland Clinic CEO Dr. Georges-Pascal Haber advocating a paradigm shift. „Current systems are reactive and hospital-centric; we need prevention-focused redesigns to keep patients healthy,“ Moulavasilis urged, emphasizing resilient infrastructure. Haber echoed the call for data-driven reforms, aligning with GITEX’s broader narrative on AI governance and ethical deployment.
Headline Innovations: Scalable Solutions for Real Impact
GITEX unveiled game-changers poised for commercialization:
- XPANCEO’s Smart Contact Lenses: Six prototypes integrated AR and biosensing, including glucose monitoring via tear fluid, intraocular pressure (IOP) sensors for glaucoma detection (with medical-grade sensitivity), and nanoparticle-enhanced color correction for color blindness. Powered by wireless tech doubling industry range, these lenses—backed by a $250 million Series A at $1.35 billion valuation—herald always-on medical wearables.
- SharedPro Technologies‘ AI Behavioral Tool: Precision autism screening and progress tracking, bridging diagnostic gaps with consistent, data-backed insights.
- HurayPositive’s AI SaaS: Tailored precision medicine for one million chronic disease patients, leveraging South Korean innovation for scalable outcomes.
- Arlan Biotech’s GenAI Platform: Redesigns antibody development, shortening R&D cycles for immunotherapy breakthroughs.
- Sonic Group’s Sonic Pill®: A wearable harnessing neuroscience algorithms and audio frequencies to boost sleep, focus, recovery, and cognition. Awarded Korea’s ‚Best Invention‘ FIRI and ARCA Croatia’s Silver for Sound Therapy, it redefines sonic wellness.
These unveilings underscore GITEX’s role in converging tech, biology, and wellness into actionable solutions, amid a $1.1 trillion investor influx and 40+ unicorns. Looking ahead, GITEX GLOBAL 2026 at Expo City Dubai kicks off with the GITEX Scale Summit on December 7, focusing on AI economies and quantum governance.
Source: GITEX
Sources:
- https://www.mammoth.bio/news/mammoth-biosciences-presents-new-data-demonstrating-ultracompact-crispr-nuclease-nancocas-for-efficient-muscle-editing-in-non-human-primates-at-asgct-2025-annual-meeting
- https://www.paradromics.com/news/paradromics-announces-first-human-implant-of-the-connexus-brain-computer-interface
- https://www.sandboxaq.com/news/sandboxaq-partners-with-bahrains-mumtalakat-to-advance-ai-and-quantum-technologies
- https://www.xpanceo.com/news/xpanceo-raises-250m-series-a-at-1-35b-valuation
- https://www.gitex.com
